Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory service provider, has announced the launch of its GuardantOMNI test, a 500-gene panel based on blood sample detection, alongside its previously introduced liquid biopsy product, Guardant360. This initiative aims to enhance the development of tumor-targeted drugs and immunotherapies in clinical trials across China.
GuardantOMNI offers comprehensive genomic analysis through a single liquid biopsy test, covering 500 genes and addressing the majority of key biomarkers in the pipeline for tumor-targeted therapies and immunotherapies.- Flcube.com
